loader2
Login Open ICICI 3-in-1 Account

Shilpa Medicare Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Shilpa Medicare Ltd. 13 Aug 2025 16:28 PM

Q1FY26 Quarterly Result Announced for Shilpa Medicare Ltd.

Pharmaceuticals company Shilpa Medicare announced Q1FY26 results

  • Total Revenue: Rs 328 crore compared to Rs 302 crore during Q1FY25, change 9%.
  • EBITDA: Rs 98 crore compared to Rs 83 crore during Q1FY25, change 18%.
  • EBITDA Margin: 30% for Q1FY26.
  • PAT: Rs 47 crore compared to Rs 14 crore during Q1FY25, change 236%.
  • PAT Margin: 14% for Q1FY26.

Vishnukant Bhutada, Managing Director, said: The first quarter of FY26 demonstrated steady progress and strong execution of our strategic priorities. Our partner successfully launched our second NDA in the US, Bortezomib RTU, reinforcing our R&D-driven approach and delivering differentiated products that enhance ease of administration. Pemetrexed also gained momentum in the U.S., while Nilotinib continued to expand its presence in the EU. Additionally, we achieved a historic milestone with NorUDCA’s approval, making Shilpa the first global company approved for NAFLD treatment. These approvals, along with our robust NDA pipeline, position us for sustained future growth.

Our API division(including captive) has reported growth of ~25% YoY basis. New product launches, CDMO expansion, expanded capacities, and an improved product mix favouring regulated markets are expected to drive further growth for FY26.

In Biologics, our strategic investment in Alveolus Bio accelerates innovation and solidifies Shilpa’s position as a global biotech enabler, bridging cutting-edge science with scalable solutions. Our Novel Biological Entities (NBEs), developed in collaboration with mAbTree and Alveolus, remain on track for Phase I human trials in FY27. On the biosimilar front, Aflibercept has advanced to Phase III clinical trials in India, while Nivolumab has completed PCT, with Phase I trials expected to commence by the end of FY26. We have also received the initial milestone payment for Recombinant Human Albumin from Orion Corporation, and the program is progressing as planned.

On the regulatory front, we continue to achieve key accreditations for our facilities. During the quarter, Unit VI at Dabaspet, Karnataka, equipped with ODF & TDP manufacturing capabilities, received an EIR from the US FDA. This milestone will support the monetisation of our differentiated product portfolio in the US market. Our focus remains on optimising asset utilisation across key verticals, and we are confident in delivering improved profitability in FY26".

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app